Development of a Stable MGAT1− CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies

Development of a Stable MGAT1− CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies

The high rate of new HIV infections, particularly in Sub-Saharan Africa, emphasizes the need for a safe and effective vaccine to prevent acquired immunodeficiency syndrome (AIDS). To date, the only HIV vaccine trial that has exhibited protective efficacy in humans was the RV144 study completed in Th...

Full description

Bibliographic Details
Main Authors: Rachel C. Doran, Bin Yu, Meredith Wright, Sara M. O'Rourke, Lu Yin, Jennie M. Richardson, Gabriel Byrne, Kathryn A. Mesa, Phillip W. Berman
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Immunology
Subjects:
HIV
gp120
Clade C
vaccine
glycosylation
cell line
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02313/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02313/full

Similar Items